Searchable abstracts of presentations at key conferences in endocrinology

ea0056p129 | Endocrine tumours and neoplasia | ECE2018

The effect of temozolomide on pancreatic neuroendocrine tumours and role of MGMT and MMR system in temozolomide resistance

Blazevic Anela , Dogan-Oruc Fadime , Dedeci Mehtap , van Koetsveld Peter M. , Feelders Richard A. , de Herder Wouter W. , Hofland Leo J.

Background: Temozolomide (TMZ) has been suggested as a treatment option for patients with pancreatic neuroendocrine tumours (PNETs). The tumour response to TMZ has been linked to expression levels of O6-methylguanine-DNA methyltransferase (MGMT) and components of the mismatch repair (MMR) system. However, there is no in vitro data on TMZ sensitivity and the expression of MGMT and MMR components in PNETs. Moreover, the effect of TMZ exposure on chemosensitivity and exp...

ea0041gp26 | Adrenal (2) | ECE2016

LCI699 is a potent inhibitor of cortisol production in vitro

Creemers Sara G , Feelders Richard A , de Jong Frank H , Franssen Gaston J H , de Rijke Yolanda B , van Koetsveld Peter M , Hofland Leo J

Introduction: The steroidogenesis inhibitors ketoconazole and metyrapone are frequently used for treatment of Cushing’s syndrome, but can cause side effects. LCI699 is a known 11β-hydroxylase inhibitor, but effects on other steroidogenic enzymes are unknown. We aimed to compare effects of LCI699, ketoconazole, and metyrapone in vitro.Methods: HAC-15 cells, with or without 10 nM ACTH, and three primary human adrenocortical adenoma cultu...

ea0037ep94 | Adrenal cortex | ECE2015

Combined effects of sirolimus and mitotane in the inhibition of growth in human adrenocortical carcinoma cells

De Martino Maria Cristina , van Koetsveld Peter M , Feeldes Richard A , Lamberts Steven W J , de Herder Wouter W , Colao Annamaria , Pivonello Rosario , Hofland Leo J

Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and scant treatment options. Mitotane alone, or in combination with cytotoxic chemotherapy, represents the referral current treatment for patients with unresectable ACC. Recent studies have shown that mTOR inhibitors suppress growth of ACC cells. This study aimed at evaluating the effects of mitotane in combination with mTOR inhibitors. In H295 and SW13 cells we tested the effects of a 6 day treatment with increa...